Nasal drug delivery specialist Kurve Technology announced that the US Department of Defense (DoD) has awarded the company a contract for testing a formulation for the treatment of traumatic brain injury (TBI). The Kurve ViaNase device is an electronic atomizer based on a controlled particle dispersion technology platform making use of vortical flow that … [Read more...] about Kurve Technology gets Defense Department contract for intranasal therapy for traumatic brain injury
Business
TFF Pharmaceuticals raises over $8 million, announces executive appointments
DPI developer TFF Pharmaceuticals said that is has raised $8.17 million through a Series A preferred stock offering and that it will use the funds for R&D. In April 2018, the company announced that it had raised $14 million for development of inhaled drugs, also through a Series A preferred stock offering. In the past year, TFF has received patents in the … [Read more...] about TFF Pharmaceuticals raises over $8 million, announces executive appointments
Acerus Pharmaceuticals licenses intranasal testosterone technology from UT Austin
Acerus Pharmaceuticals said that it has acquired exclusive worldwide rights to technology related to intranasal delivery of testosterone from the University of Texas at Austin. The company said that the agreement covers the use of the intranasal testosterone technology "in all applicable fields." Formerly known as Trimel, Acerus previously developed Natesto … [Read more...] about Acerus Pharmaceuticals licenses intranasal testosterone technology from UT Austin
BlueWillow announces US patent for intranasal anthrax vaccine
According to BlueWillow Biologics, the University of Michigan has been issued US patent No. 10,138,279 which covers an intranasal anthrax vaccine formulated with BlueWillow's NanoVax adjuvant. BlueWillow (formerly NanoBio) is a spin out from the University of Michigan and has an exclusive license to the anthrax vaccine. The company said that its partner … [Read more...] about BlueWillow announces US patent for intranasal anthrax vaccine
Insmed raises $250 million in public stock offering
Insmed Incorporated said that a just-closed public stock offering generated net proceeds of about $235.5 million that will be used for continuing commercialization of Arikayce amikacin liposome inhalation suspension (ALIS). The offering of 9,615,385 shares of common stock at $26.00/share resulted in gross proceeds of about $250 million. The underwriters of the … [Read more...] about Insmed raises $250 million in public stock offering
According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
Vectura Group and Sosei Group each said that they are owed $2.5 million milestone payments from Novartis after the EU accepted Novartis's MAA for its QVM149 indacaterol/glycopyrronium/mometasone furoate DPI for the treatment of asthma that is inadequately controlled. Vectura said that approval of the MAA would trigger an additional milestone payment of $5 million. … [Read more...] about According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
AMSL Diabetes to distribute Afrezza inhaled insulin in Australia
MannKind Corporation has announced that signed a marketing and distribution agreement with Australasian Medical & Scientific Ltd division AMSL Diabetes for commercialization of Afrezza inhaled insulin in Australia. AMSL Diabetes will take responsibility for getting Australian regulatory and reimbursement approval for Afrezza and for sales, marketing, and … [Read more...] about AMSL Diabetes to distribute Afrezza inhaled insulin in Australia
Pneuma Respiratory licenses mAbs from Leads Biolabs for development of inhaled immuno-oncology therapy
Pneuma Respiratory has announced a licensing agreement with Nanjing Leads Biolabs subsidiary Leads Biolabs, Inc. for rights to develop Leads monoclonal antibodies and fusion protein molecules for delivery using Pneuma's digital soft mist inhaler. Pneuma said that it plans to develop inhaled immuno-oncology drugs. Pneuma Respiratory CEO and Co-Founder Eric Hunter … [Read more...] about Pneuma Respiratory licenses mAbs from Leads Biolabs for development of inhaled immuno-oncology therapy
Milestone Pharmaceuticals raises $82.5 million in IPO
Etripamil developer Milestone Pharmaceuticals announced that its recently closed initial public offering raised approximately $82.5 million gross by selling 5,500,000 common shares at $15/share. The company is developing intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). The intranasal calcium channel antagonist, also known … [Read more...] about Milestone Pharmaceuticals raises $82.5 million in IPO
Vectura awarded $89.7 million in Ellipta patent infringement suit
According to Vectura, a jury has found that US sales of several of GlaxoSmithKline's Ellipta DPIs infringed on Vectura’s US patent 8303991 ("Method of making particles for use in a pharmaceutical composition"). The jury awarded Vectura $89.7 million in damages and found that GSK willfully infringed on the patent, allowing Vectura to ask for enhanced … [Read more...] about Vectura awarded $89.7 million in Ellipta patent infringement suit